CD133 Expression in Medullary Thyroid Cancer Cells Identifies Patients with Poor Prognosis.

The identification of markers able to determine medullary thyroid cancer (MTC) patients at high-risk of disease progression is critical to improve their clinical management and outcome. Previous studies have suggested that expression of the stem cell marker CD133 is associated with MTC aggressivenes...

Descripción completa

Detalles Bibliográficos
Autores: Cordero-Barreal, Alfonso, Caleiras, Eduardo, López de Maturana, Evangelina, Monteagudo, María, Martínez-Montes, Ángel M, Letón, Rocío, Gil, Eduardo, Álvarez-Escolá, Cristina, Regojo, Rita M, Andía, Víctor, Marazuela, Mónica, Guadalix, Sonsoles, Calatayud, María, Robles-Díaz, Luis, Aguirre, Miguel, Cano, Juana M, Díaz, José Ángel, Saavedra, Pilar, Lamas, Cristina, Azriel, Sharona, Sastre, Julia, Aller, Javier, Leandro-García, Luis J, Calsina, Bruna, Roldán-Romero, Juan María, Santos, María, Lanillos, Javier, Cascon Soriano, Alberto, Robledo Batanero, Mercedes, Montero-Conde, Cristina, Rodriguez Antona, Cristina
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/27205
Acceso en línea:https://hdl.handle.net/20.500.12105/27205
Access Level:acceso abierto
Palabra clave:RAS
RET
calcitonin expression and tumor emboli
disease progression
immunohistochemistry
Descripción
Sumario:The identification of markers able to determine medullary thyroid cancer (MTC) patients at high-risk of disease progression is critical to improve their clinical management and outcome. Previous studies have suggested that expression of the stem cell marker CD133 is associated with MTC aggressiveness.

Similares en LA Referencia